Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more) Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioXcel Therapeutics Inc BTAI

Healthcare Biotechnology
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.


NDAQ:BTAI - Post by User

BioXcel Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 2:07pm
34 Views
Post# 36161490

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Advancing Neurosci

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Advancing Neuroscihttps://beyondspx.com/2024/07/31/bioxcel-therapeutics-inc-nasdaqbtai-advancing-neuroscience-and-immuno-oncology-pipelines-driving-igalmi-commercialization/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities